Novo Nordisk A/S (NYSE:NVO) was downgraded by research analysts at TheStreet from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

NVO has been the topic of several other research reports. DNB Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, October 31st. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday, October 13th. Citigroup Inc. lowered Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Monday, October 31st. Zacks Investment Research lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, September 6th. Finally, Bank of America Corp. lowered Novo Nordisk A/S from a “neutral” rating to an “underperform” rating in a research note on Friday, October 28th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $61.33.

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Shares of Novo Nordisk A/S (NYSE:NVO) opened at 32.98 on Friday. The company has a 50-day moving average of $39.22 and a 200 day moving average of $48.79. The stock has a market capitalization of $83.32 billion, a price-to-earnings ratio of 15.12 and a beta of 0.84. Novo Nordisk A/S has a 12-month low of $32.80 and a 12-month high of $59.00.

Several large investors have recently added to or reduced their stakes in NVO. Jennison Associates LLC increased its stake in Novo Nordisk A/S by 16.4% in the second quarter. Jennison Associates LLC now owns 17,400,801 shares of the company’s stock worth $935,815,000 after buying an additional 2,452,120 shares during the period. Sustainable Growth Advisers LP increased its stake in Novo Nordisk A/S by 34,479.6% in the third quarter. Sustainable Growth Advisers LP now owns 1,864,530 shares of the company’s stock worth $77,546,000 after buying an additional 1,859,138 shares during the period. Morgan Stanley increased its stake in Novo Nordisk A/S by 88.6% in the third quarter. Morgan Stanley now owns 3,012,074 shares of the company’s stock worth $125,273,000 after buying an additional 1,415,016 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Novo Nordisk A/S during the third quarter worth approximately $51,330,000. Finally, Capital International Investors increased its stake in Novo Nordisk A/S by 39.3% in the third quarter. Capital International Investors now owns 2,690,700 shares of the company’s stock worth $111,906,000 after buying an additional 758,600 shares during the period. 6.94% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

5 Day Chart for NYSE:NVO

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.